Diligence memo · auto-generated · as of July 2, 2026
DalCor Pharmaceuticals US, LLC
DalCor Pharmaceuticals US, LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
DalCor Pharmaceuticals US, LLC operates in Pharmaceuticals, based in Sarasota.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
DalCor Pharmaceuticals US, LLC has raised $20M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $55M on 2016-04-29.
Most recent recorded round closed around 2020-05-12.
Valuation (modeled)modeled
Provath models DalCor Pharmaceuticals US, LLC at approximately $131M (range $8.1M–$504M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.26× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 67% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Evolus, Inc., HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.